Bank of Nova Scotia Trust Co. Acquires 661 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Bank of Nova Scotia Trust Co. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 26.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,182 shares of the medical research company's stock after purchasing an additional 661 shares during the quarter. Bank of Nova Scotia Trust Co.'s holdings in Thermo Fisher Scientific were worth $1,583,000 at the end of the most recent quarter.

• Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase

A number of other hedge funds have also added to or reduced their stakes in the business. J. Safra Sarasin Holding AG increased its holdings in Thermo Fisher Scientific by 2.5% in the first quarter. J. Safra Sarasin Holding AG now owns 35,255 shares of the medical research company's stock worth $17,544,000 after purchasing an additional 844 shares in the last quarter. Malaga Cove Capital LLC grew its stake in Thermo Fisher Scientific by 44.7% in the first quarter. Malaga Cove Capital LLC now owns 2,492 shares of the medical research company's stock valued at $1,240,000 after acquiring an additional 770 shares during the period. Pathway Financial Advisers LLC grew its stake in Thermo Fisher Scientific by 4.1% in the first quarter. Pathway Financial Advisers LLC now owns 1,385 shares of the medical research company's stock valued at $689,000 after acquiring an additional 55 shares during the period. Banco Santander S.A. grew its stake in Thermo Fisher Scientific by 14.0% in the first quarter. Banco Santander S.A. now owns 87,286 shares of the medical research company's stock valued at $43,434,000 after acquiring an additional 10,714 shares during the period. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its stake in Thermo Fisher Scientific by 7.6% in the first quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 111,210 shares of the medical research company's stock valued at $55,338,000 after acquiring an additional 7,814 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research reports. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. Robert W. Baird raised their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Finally, Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Six analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

• Agilent Technologies Thrives From the Forever Chemicals Crackdown

Get Our Latest Research Report on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 1.1%

TMO stock opened at $462.74 on Friday. The stock's fifty day simple moving average is $420.88 and its two-hundred day simple moving average is $467.66. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The stock has a market cap of $174.68 billion, a P/E ratio of 26.76, a P/E/G ratio of 2.50 and a beta of 0.77.

• Top 4 Fastest Growing S&P 500 Dividends: Buy, Sell, or Hold?

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 earnings per share. The business's revenue was up 2.9% on a year-over-year basis. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

• Five stocks we like better than Thermo Fisher Scientific
• How to Calculate Return on Investment (ROI)
• Will Hims & Hers Fall Along With Novo Nordisk?
• Best Stocks Under $10.00
• Play It Cool: Why Comfort Systems USA Is a Hidden AI Winner
• What is Short Interest? How to Use It
• Rocket Lab Reports Next Week: Here’s What Investors Should Know

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Thermo Fisher Scientific Right Now?

Before you consider Thermo Fisher Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.

While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here